Aurobindo receives FDA OK for generic Furadantin
Nitrofurantoin oral suspension is indicated for the treatment of certain urinary tract infections.
Aurobindo has received the green light from the Food and Drug Administration for nitrofurantoin oral suspension 25 mg/5 ml, which is the generic of Casper Pharma’s Furadantin.
Nitrofurantoin oral suspension is indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci, Staphylococcus aureus and certain susceptible strains of Klebsiella and Enterobacter species.
[Read more: Aurobindo receives FDA approval for 3 generics]
Nitrofurantoin oral suspension has a market value of roughly $55 million for the 12 months ending March 2023, per IQVIA.
[Read more: Aurobindo obtains FDA OK for 2 generics]